Viking Therapeutics (VKTX) : Traders are bullish on Viking Therapeutics (VKTX) as it has outperformed the S&P 500 by a wide margin of 4.35% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 8.43%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 8.61% in the last 1 week, and is up 3.79% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 6.47% and the 50-Day Moving Average is 5.32%.The 200 Day SMA reached 13.19%
Viking Therapeutics (NASDAQ:VKTX): After opening at $1.37, the stock dipped to an intraday low of $1.36 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $1.45 and the buying power remained strong till the end. The stock closed at $1.4011 for the day, a gain of 3.02% for the day session. The total traded volume was 656,471. The stocks close on the previous trading day was $1.4011.
Viking Therapeutics (VKTX) : The most positive equity analysts on Viking Therapeutics (VKTX) expects the shares to touch $9, whereas, the least positive believes that the stock will trade at $5 in the short term. The company is covered by 4 Wall Street Brokerage Firms. The average price target for shares are $7.06 with an expected fluctuation of $1.92 from the mean.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211, which is an orally available drug candidate under a Phase II clinical trial. Its second clinical program is focused on the development of molecule agonists of the thyroid receptor beta (TRB), for adrenoleukodystrophy (ALD) and lipid disorders, such as hypercholesterolemia and non-alcoholic steatohepatitis (NASH). The Company is also engaged in developing VK2809 and VK0214 for the treatment and potential prophylaxis of ALD. Its VK0612 is an orally available Phase IIb-ready drug candidate for type 2 diabetes. The Companys preclinical programs are focused on identifying erythropoietin receptor (EPOR) agonists, for the treatment of anemia and on the development of tissue-selective inhibitors of diacylglycerol acyltransferase-1 (DGAT-1), for the treatment of obesity and dyslipidemia.